Figure 5.
Systemic delivery of rAAV9 carrying miR-34a-5p reverses osteoporosis in mice
(A) Diagram of the study and treatment methods. 24-month-old male mice were i.v. injected with a single dose of rAAV9 (5 × 1013 kg/vg) carrying ctrl or miR-214-3p TuD or miR-34a-5p and, 7 weeks later, mice were injected with calcein/AR for dynamic histomorphometry analysis. (B) miR-214-3p or miR-34a-5p expression in the tibia was measured by RT-PCR and normalized to U6 (n = 5). (C and F) The femoral bone mass of rAAV-treated mice was assessed by microCT. 3D reconstruction (C and F) (left) and relative quantification (C and F) (right) are displayed (n = 5). (D and G) Representative images of calcein/AR labeling and relative histomorphometric quantification of BFR/BS and MAR are displayed (n = 5). (E and H) Serum levels of CTX-I in AAV-treated mice were assessed by ELISA (n = 5). Scale bars, 50 μm in (D and G). Values represent mean ± SD: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by an unpaired two-tailed Student’s t test.